Stockscreener 앱 받기
138.11
0.56%
0.77
시장 영업 전:
138.67
0.56
+0.41%
전일 마감가:
$137.34
열려 있는:
$136.8
하루 거래량:
6.72M
Relative Volume:
0.93
시가총액:
$171.45B
수익:
$29.45B
순이익/손실:
$8.51B
주가수익비율:
20.36
EPS:
6.7823
순현금흐름:
$9.46B
1주 성능:
-4.36%
1개월 성능:
-6.45%
6개월 성능:
+21.50%
1년 성능:
+29.39%
1일 변동 폭
$136.47
$138.37
1주일 범위
$136.44
$143.79
52주 변동 폭
$93.37
$157.29
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
138.11 | 171.45B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
903.02 | 806.39B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
235.27 | 566.67B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
205.20 | 362.83B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
185.78 | 288.11B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
116.37 | 287.71B | 64.93B | 18.26B | 12.36B | 7.2751 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Gilead Eyes $2.2 Billion Autoimmune Push With Ouro Deal - GuruFocus
Market Today: Oil Rebounds; Disney Exits OpenAI Deal; Gilead Buys Ouro - GuruFocus
Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro Acquisition - MedCity News
Clear Street reiterates Cullinan Oncology stock rating on Gilead deal validation - Investing.com
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition - Benzinga
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition - Benzinga
Gilead Sciences Inc and Arcus Biosciences Inc Post ARC-7 Plenary Q&A Transcript - GuruFocus
Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout - Pharmaceutical Technology
Gilead’s $2.2bn buy of Ouro Medicines includes Galapagos alliance - BioXconomy
Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases - BioPharma Dive
Gilead acquires potential first-in-class T cell engager in $2bn deal with Ouro Medicines - European Pharmaceutical Review
Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. - Barron's
Gilead Sciences buys Ouro Medicines in deal worth up to $2.18 billion - Новости GxP
Bernstein reiterates Gilead stock rating on Ouro acquisition - Investing.com
Scotiabank Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $177 - Moomoo
Gilead Chief Gets 20% Pay Bump, Still Falls Short of $30M Club - BioSpace
Gilead Drops $2.1B for Ouro, Hopes To Split Cost with Galapagos - BioSpace
Goldman Sachs reiterates Neutral on Gilead stock after Ouro deal - Investing.com
Gilead to Acquire Ouro Medicines in Over $2 Billion Deal - eHealth Magazine
This pharma company’s twice-yearly shot is putting the end of HIV/AIDS within reach - Fast Company
Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio - Proactive financial news
E. Ohman J or Asset Management AB Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos - Fierce Biotech
Gilead Sciences (GILD) Acquires Ouro Medicines for $1.675 Billio - GuruFocus
Gilead nearing $2B takeout of Ouro: report - FirstWord Pharma
Gilead Sciences to buy Ouro Medicines to boost T cell therapy for autoimmune diseases (GILD:NASDAQ) - Seeking Alpha
M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth - TipRanks
Keymed Biosciences shares rise on $320 mln windfall from Gilead-Ouro deal - Investing.com
Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal - Stocktwits
Gilead snags another local company, this one launched little more than a year ago - The Business Journals
Gilead boosts immunology pipeline with over $2 billion buyout of Ouro Medicines - KELO-AM
Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets - WSJ
Gilead nears up to $2 billion buyout of biotech Ouro Medicines, FT reports By Reuters - Investing.com
Gilead (GILD) Expands Portfolio with Acquisition of Ouro Medicines - GuruFocus
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal By Reuters - Investing.com
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal - AOL.com
Gilead to buy Ouro Medicines for up to $2.2 billion By Investing.com - Investing.com India
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - The Manila Times
Gilead Sciences to acquire Ouro Medicines in push for autoimmune disease therapies - Traders Union
Gilead to buy Ouro Medicines for up to $2.2 billion - Investing.com
Gilead to acquire Ouro Medicines for up to $2.18 billion By Investing.com - Investing.com India
Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases - TradingView
Gilead to Buy Ouro Medicines for Its Autoimmune Drugs - Bloomberg.com
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases - Business Wire
Gilead Sciences (GILD) Nears $2 Billion Acquisition of Ouro Medi - GuruFocus
Gilead (GILD) Edges Toward $2 Billion Acquisition of Ouro Medici - GuruFocus
Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports - Yahoo Finance
Gilead Sciences nears $2 billion Ouro Medicines acquisition - Investing.com South Africa
Gilead nears up to $2 billion buyout of biotech Ouro Medicines, FT reports - marketscreener.com
Gilead nears up to $2bn deal for autoimmune biotech Ouro Medicines - Financial Times
Gilead Sciences Inc (XSWX:GILD) Stock Earnings Transcripts - GuruFocus
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
길리어드 사이언스 주식 (GILD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Mar 16 '26 |
Sale |
144.23 |
3,000 |
432,690 |
179,191 |
0.19%
0.38%
자본화:
|
볼륨(24시간):